Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.58 |
| ▸ | BRD9 | Q9H8M2 | 6/20 | 0.58 |
| ▸ | BRD2 | P25440 | 1/20 | 0.44 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19869730 | 0.94 | BRD4 (0.56) | BRD4BRD9BRD2BRD7CYP2C9 | |
| SCHEMBL19869723 | 0.84 | BRD4 (0.53) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL19869733 | 0.81 | BRD4 (0.58) | BRD4BRD9CYP2C9HSD11B1CYP2C19 | |
| SCHEMBL19869716 | 0.78 | BRD4 (0.61) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL24556579 | 0.76 | BRD4 (0.73) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL19869758 | 0.76 | BRD4 (0.51) | BRD4BRD9CYP2C9HSD11B1CYP2C19 | |
| SCHEMBL19869834 | 0.74 | BRD4 (1.00) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL19869754 | 0.73 | BRD4 (0.69) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL24556388 | 0.73 | BRD4 (1.00) | BRD4BRD9 | |
| SCHEMBL19869670 | 0.72 | BRD4 (0.59) | BRD4BRD9BRD2BRD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | BRD4 5/4885BRD9 1/4885BRD2 3/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | BRD4 6/4885BRD9 1/4885BRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.